LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062646 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ryo Otsuka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, ATP-Binding Cassette, Sub-Family C Proteins, Spheroids, Cellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Grant-in-Aid for Research in Nagoya City University.
Abstract (Originalsprache)
Leucine-rich repeat-containing 8A (LRRC8A; also known as SWELL1), the essential subunit of volume-regulated anion channels (VRACs), is amplified in multiple malignancies and has been implicated in tumor progression and therapeutic resistance. Three-dimensional (3D) cancer spheroids have been well-established as in vitro models that recapitulate characteristics of tumor stemness and intrinsic drug resistance. In the present study, spheroid formation in human breast cancer cell lines, YMB-1 and MDA-MB-468, conferred resistance to multiple anticancer drugs, including doxorubicin (DOX), gemcitabine (GEM), and 5-fluorouracil (5-FU), thereby mimicking the characteristic properties of breast cancer stem-like cells. LRRC8A expression was upregulated in 3D spheroids compared with adherent 2D monolayers, and its pharmacological inhibition induced membrane hyperpolarization accompanied by intracellular Cl− accumulation. Inhibition of LRRC8A significantly sensitized spheroids to DOX, GEM, and 5-FU. Spheroid formation increased the expression of multidrug resistance-related protein 3 (MRP3) and the drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4), whereas LRRC8A inhibition suppressed their expression. The transcriptional upregulation of MRP3 and CYP3A4 was mediated through the NRF2–CEBPB/D transcriptional axis. Collectively, these findings suggest that LRRC8A inhibition may represent a therapeutic strategy to overcome chemoresistance by repressing MRP3 and/or CYP3A4 expression in breast cancer stem cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
- Department of Breast Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
ORCID-Profile: Junko Kajikuri, Yohei Yamaguchi, Susumu Ohya
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Grant-in-Aid for Research in Nagoya City University
- JSPS KAKENHI
- Nagoya City University
- MEXT Project
Zitieren
APA
Otsuka, R., Kajikuri, J., Matsui, M., Kito, H., Kitahara, A., Mitsui, H., Yamaguchi, Y., Hisada, T., Toyama, T., & Ohya, S. (2026). LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062646
Vancouver
Otsuka R, Kajikuri J, Matsui M, Kito H, Kitahara A, Mitsui H, et al. LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062646
BibTeX
@article{Otsuka2026,
author = {Otsuka, Ryo and Kajikuri, Junko and Matsui, Miki and Kito, Hiroaki and Kitahara, Ayano and Mitsui, Hinako and Yamaguchi, Yohei and Hisada, Tomoka and Toyama, Tatsuya and Ohya, Susumu},
title = {LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062646}
}
EUVIMED